Abacavir
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
ABACAVIR (DB01048): Drug Repurposing Evaluation — Insufficient Data to Complete Assessment
One-Sentence Summary
ABACAVIR is an antiretroviral agent (DrugBank ID: DB01048) that was queried for drug repurposing potential via the TxGNN pipeline. However, this Evidence Pack contains no predicted indications, no original indication records, and no safety data — the evaluation cannot proceed beyond the preliminary stage. The data collection phase must be completed before any repurposing direction can be assessed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no regulatory records found) |
| Predicted New Indication | Not available (no TxGNN predictions in this pack) |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — pipeline incomplete |
| Market Status (Taiwan) | Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why No Prediction Is Available
This Evidence Pack (version v4, candidate TW-DB01048-multi) was generated with only one data source successfully retrieved: DrugBank (query ID 3, returned 1 record). Two critical data gaps were flagged at the time of pack creation:
| Gap ID | Item | Severity | Impact |
|---|---|---|---|
| DG001 | TFDA package insert warnings / contraindications | Blocking | Cannot enter Safety S1 screening |
| DG002 | Mechanism of action (MOA) | High | Cannot perform mechanistic relevance analysis |
Because the TFDA regulatory query (query ID 1) returned zero records and the predicted_indications array is empty, no repurposing candidate has been generated for ABACAVIR in this pipeline run. Without a predicted indication, sections covering clinical trial evidence, literature evidence, mechanism rationale, and cytotoxicity assessment cannot be produced.
Market Information (Taiwan)
No Taiwan TFDA license records were found for ABACAVIR. The drug is currently not marketed in Taiwan under any registered product.
Safety Considerations
Please refer to the package insert for safety information. No safety data (warnings, contraindications, or drug interactions) was retrievable in this pipeline run.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack is structurally incomplete — the TxGNN prediction pipeline did not produce any candidate indications for ABACAVIR, and all safety screening inputs are missing. No forward evaluation is possible in this state.
To proceed, the following is needed:
- Retrieve TFDA package insert — Download and parse the official TFDA PDF for ABACAVIR to populate warnings, contraindications, and approved indications. This resolves the Blocking gap (DG001) and unblocks S1 safety screening.
- Retrieve MOA from DrugBank API — Query
https://api.drugbank.com/v1/drugs/DB01048for the mechanism of action field to resolve DG002 and enable mechanistic analysis. - Re-run the TxGNN prediction pipeline — Once original indications and MOA are populated, re-execute the KG and DL prediction steps to generate
predicted_indications. - Re-run evidence collectors — After predictions are available, trigger ClinicalTrials.gov, PubMed, and ICTRP collectors to populate clinical trial and literature evidence for the top predicted indication.
- Regenerate Evidence Pack v5 — With all inputs resolved, a complete evaluation report can be produced.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.